Celgene announced that after consulting the data safety and monitoring committee that was overseeing the main mongersen study, called REVOLVE, it had decided to stop developing the drug. It cited a futility analysis, implying the medicine was not effective, but said there were no safety problems.
from Forbes Real Time https://www.forbes.com/sites/matthewherper/2017/10/19/drug-celgene-bought-for-710-million-fails/
via IFTTT
No comments:
Post a Comment